Adi Diab

22.8k citations

194 papers · 5.2k indexed · 1 hit paper · h-index 38

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
Immunology top 1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology

Papers in

Oncology 164
- Cancer Immunotherapy and Biomarkers 138
- CAR-T cell therapy research 65
- Colorectal Cancer Treatments and Studies 22
- Cutaneous Melanoma Detection and Management 14
Immunology 69
- Immunotherapy and Immune Responses 57
- Immune Cell Function and Interaction 14

Co-authors: María E. Suarez‐Almazor Noha Abdel‐Wahab Daniel H. Johnson Michael T. Tetzlaff Van Anh Trinh Sapna P. Patel Jonathan L. Curry Patrick Hwu
Journals: Journal of Clinical Oncology (65 papers)Annals of Oncology (21 papers)Journal for ImmunoTherapy of Cancer (11 papers)Cancer Research (9 papers)Journal of Cutaneous Pathology (5 papers)
Partner nations: United States Australia Egypt

In The Last Decade

Adi Diab

186 papers receiving 5.1k citations

Hit Papers

align trajectories log scale

Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? 2014 · 255 citations

Peers

Countries citing papers authored by Adi Diab

Since Specialization

Citations

This map shows the geographic impact of Adi Diab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Diab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Diab more than expected).

Fields of papers citing papers by Adi Diab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adi Diab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Diab. The network helps show where Adi Diab may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Adi Diab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Adi Diab Line = papers co-authored together Adi Diab links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma OncoImmunology ·Éric Brangier, Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab, Jeffrey E. Gershenwald, Isabella C. Glitza, Jeffrey E. Lee, Anthony Lucci, Jennifer L. McQuade, Sapna P. Patel, Merrick I. Ross, Hussein A. Tawbi, Jennifer A. Wargo, Michael K. Wong, Chantale Bernatchez, Patrick Hwu, Cara Haymaker, Rodabe Navroze Amaria	2025	0
2	Clinical and Imaging Predictors of False-Positive and False-Negative Results in Prostate Multiparametric MRI Using PI-RADS Version 2 Radiology Imaging Cancer ·Sirks A.J.B., Jonathan P. Troost, Sonia Gaur, Prasad R. Shankar, Adi Diab, Mohala Kaliebe, Benjamin M. Mervak, Shokoufeh Khalatbari, Matthew S. Davenport	2025	0
3	The DIET study: A randomized controlled trial of a high fiber diet intervention (HFDI) in patients (pts) with melanoma receiving immune checkpoint blockade (ICB). Journal of Clinical Oncology ·Mathieu Gayral, C Vieira da Silva, Maria Paula Van Tol Aragão da Silveira, Erma Levy, شهره نصیرآبادی, Justin Rains, Elizabeth Sirmans, Elizabeth M. Burton, Jian Wang, Rodabe N. Amaria, Michael A. Davies, Isabella Claudia Glitza, Sapna P. Patel, Adi Diab, Hussein A. Tawbi, Michael K. Wong, Alexandra P. Ikeguchi, Jennifer A. Wargo, Carrie R. Daniel, Jennifer L. McQuade	2024	2
4	OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. Journal of Clinical Oncology ·Rodabe N. Amaria, Jennifer L. McQuade, Michael A. Davies, Isabella Claudia Glitza, Edwin Stanly Escobar-Pineda, Erik N. K. Cressman, 傅淳, Roland L. Bassett, Sapna P. Patel, Adi Diab, Hussein A. Tawbi, Michael K. Wong, Alexandra P. Ikeguchi, Cara Haymaker, Nathally Botoluzzi, Madan Jagasia, Giridharan Ramsingh, Prakash Prabhakar, Cassidy M. Spaeth, Parameswaran Hari	2024	17
5	Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma Neuro-Oncology Practice ·Chantal Saberian, Denái R. Milton, Julie M. Simon, Rodabe N. Amaria, Adi Diab, Jennifer L. McQuade, Sapna P. Patel, Hussein A. Tawbi, Cassian Yee, Michael K. Wong, Ian E. McCutcheon, Michael A. Davies, Sherise D. Ferguson, Isabella C. Glitza Oliva	2024	1
6	Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial Cancer Immunology Immunotherapy ·F. Segrove, Amy K. Erbe, Jennifer Birstler, KyungMann Kim, Ute Hoch, Sue Currie, Pravastaningrum Yuliantina, Danni Yu, Arlene O. Siefker‐Radtke, Nizar M. Tannir, Sara M. Tolaney, Adi Diab, Paul M. Sondel	2023	2
7	Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response Cancers ·朱连清, Umut Selamet, Consol López San Martín, Omar Mamlouk, Juhee Song, M.Y. Lev, Maen Abdelrahim, Adi Diab, Noha Abdel‐Wahab, Ala Abudayyeh	2023	8
8	Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis Annals of the Rheumatic Diseases ·Anne R. Bass, Noha Abdel‐Wahab, Pankti Reid, Jeffrey A. Sparks, Cassandra Calabrese, Deanna Jannat‐Khah, Nilasha Ghosh, J. Russ, Tomoko Tuzino, Lydia Gedmintas, Lindsey A. MacFarlane, L. Aschauer, Adewunmi Falohun, Kamil Kleszcz, Erika-Julieth Pinzón-Ibáñez, Adi Diab, Ami A. Shah, Clifton O. Bingham, Karmela K Chan, Laura C. Cappelli	2023	39
9	Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study Cancers ·María A. López-Olivo, Gabrielle F. Duhon, Yuzhen Zhang, Mehmet Altan, Hussein A. Tawbi, Adi Diab, Clifton O. Bingham, Cassandra Calabrese, Natalia I. Heredia, Robert J. Volk, María E. Suarez‐Almazor	2023	4
10	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer ·Omid Hamid, Alberto Chiappori, John A. Thompson, Toshihiko Doi, Siwen Hu‐Lieskovan, Ferry A.L.M. Eskens, Willeke Ros, Adi Diab, Jean‐Philippe Spano, Naiyer A. Rizvi, Jeffrey S. Wasser, Eric Angevin, Patrick A. Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B. El-Khoueiry	2022	37
11	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study Journal for ImmunoTherapy of Cancer ·Nizar M. Tannir, Normand Poulet, Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, Elodie Herail, David Chien, Ute Hoch, Susumu Kuzuhara, Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Arlene O. Siefker‐Radtke, Michael E. Hurwitz	2022	21
12	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases npj Breast Cancer ·David B. Page, Kathryn Beal, Stefanie N. Linch, Kateri J. Spinelli, Eunice Wageci Kagucia, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J. Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A. Barker, Adi Diab, Larry Norton, Heather L. McArthur	2022	25
13	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit Cancer ·Anisha B. Patel, Syed Mazhar Ali Shah, Kazuo Chin, Rodabe N. Amaria, Susan Y. Chon, Adi Diab, Isabella C. Glitza Oliva, Auris Huen, Qiongfan, Kelly C. Nelson, Omar Pacha, Sapna P. Patel, Ronald P. Rapini, Hussein A. Tawbi, Michael K. Wong, Jennifer L. McQuade, Michael A. Davies, Lauren E. Haydu	2021	13
14	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules Clinical Cancer Research ·Georgina V. Long, Caroline Robert, Marcus O. Butler, Félix Couture, Matteo S. Carlino, Steven O’Day, Victoria Atkinson, Jonathan Cebon, Michael P. Brown, Stéphane Dalle, Andrew Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, 吉博大沢, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab	2021	24
15	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma Clinical Cancer Research ·Anthony Lucci, Carolyn Hall, Sapna P. Patel, Andre Yuda Pranata, Jessica B. Bauldry, Richard E. Royal, Mandar Karhade, Siyao Ju, Jennifer A. Wargo, Isabella C. Glitza, Michael K. Wong, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael A. Davies, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Merrick I. Ross	2020	52
16	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors Cancer Discovery ·Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W. Hudgens, Harriet M. Kluger, Michael T. Tetzlaff, Mary Tagliaferri, Jonathan Zalevsky, Ute Hoch, Christie Fanton, Sandra Aung, Patrick Hwu, Brendan D. Curti, Nizar M. Tannir, Mario Sznol, Adi Diab	2019	169
17	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy Cancer Immunology Research ·Daniel H. Johnson, Anisha B. Patel, Marc Uemura, Van Anh Trinh, Natalie Jackson, Chrystia M. Zobniw, Michael T. Tetzlaff, Patrick Hwu, Jonathan L. Curry, Adi Diab	2019	91
18	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model Clinical Cancer Research ·Sharareh Niknam, Hampartsoum B. Barsoumian, Jonathan E. Schoenhals, Luis Alberto Sánches Bazán, Niranjan Yanamandra, Mauricio S. Caetano, Ailin Li, Ahmed Younes, Alexandra P. Cadena, Taylor R. Cushman, Joe Y. Chang, Q.N. Nguyen, Daniel R. Gomez, Adi Diab, John V. Heymach, Patrick Hwu, María Angélica Cortez, James W. Welsh	2018	46
19	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features American Journal of Dermatopathology ·Michael T. Tetzlaff, Priyadharsini Nagarajan, Susan Y. Chon, Auris Huen, Adi Diab, Omar Pacha, Phyu P. Aung, Carlos A. Torres‐Cabala, Steven R. Mays, Víctor G. Prieto, Jonathan L. Curry	2017	82
20	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	2016	251

About Adi Diab

Adi Diab is a scholar working on Oncology, Immunology, Biotechnology, Pulmonary and Respiratory Medicine and Genetics, having authored 194 papers that have together received 5.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (138 papers), CAR-T cell therapy research (65 papers), Immunotherapy and Immune Responses (57 papers), Melanoma and MAPK Pathways (29 papers), Colorectal Cancer Treatments and Studies (22 papers), Brain Metastases and Treatment (19 papers), Cutaneous Melanoma Detection and Management (14 papers) and Immune Cell Function and Interaction (14 papers). The work is most often cited by research in Oncology (4.0k citations), Immunology (2.0k citations), Genetics (351 citations), Pulmonary and Respiratory Medicine (923 citations) and Transplantation (70 citations). Adi Diab has collaborated with scholars based in United States, Australia and Egypt. Frequent co-authors include María E. Suarez‐Almazor, Noha Abdel‐Wahab, Daniel H. Johnson, Michael T. Tetzlaff, Van Anh Trinh, Sapna P. Patel, Jonathan L. Curry, Patrick Hwu, Chrystia M. Zobniw and Carlos A. Torres‐Cabala. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal for ImmunoTherapy of Cancer, Cancer Research and Journal of Cutaneous Pathology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact